A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders

Melbourne Genomics Health Alliance

Research output: Contribution to journalArticlepeer-review

234 Citations (Scopus)

Abstract

Purpose: To prospectively evaluate the diagnostic and clinical utility of singleton whole-exome sequencing (WES) as a first-tier test in infants with suspected monogenic disease.

Methods: Singleton WES was performed as a first-tier sequencing test in infants recruited from a single pediatric tertiary center. This occurred in parallel with standard investigations, including single- or multigene panel sequencing when clinically indicated. The diagnosis rate, clinical utility, and impact on management of singleton WES were evaluated.

Results: Of 80 enrolled infants, 46 received a molecular genetic diagnosis through singleton WES (57.5%) compared with 11 (13.75%) who underwent standard investigations in the same patient group. Clinical management changed following exome diagnosis in 15 of 46 diagnosed participants (32.6%). Twelve relatives received a genetic diagnosis following cascade testing, and 28 couples were identified as being at high risk of recurrence in future pregnancies.Conclusions:This prospective study provides strong evidence for increased diagnostic and clinical utility of singleton WES as a first-tier sequencing test for infants with a suspected monogenic disorder. Singleton WES outperformed standard care in terms of diagnosis rate and the benefits of a diagnosis, namely, impact on management of the child and clarification of reproductive risks for the extended family in a timely manner.

Original languageEnglish
Pages (from-to)1090-1096
Number of pages7
JournalGENETICS IN MEDICINE
Volume18
Issue number11
DOIs
Publication statusPublished - Nov 2016
Externally publishedYes

Keywords

  • clinical utility
  • first tier
  • monogenic
  • singleton WES

Fingerprint

Dive into the research topics of 'A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders'. Together they form a unique fingerprint.

Cite this